EAU26 was great!
It was a pleasure connecting with so many urologists and professionals committed to advancing prostate cancer diagnosis. A standout moment…
News
Will we see you at EAU?
PCaVision will be attending EAU26 The EAU Congress is one of the leading global events in urology, bringing together healthcare…
Successful crowdfunding!
PCaVision’s INVESDOR crowdfunding is now successfully closed at €2,826,137 invested by 449 investors. A big thank you to all investors who…
PCaVision will attend the ESU-ESUT-ESUI Masterclass on Focal therapy for localized prostate cancer
Focal Therapy (FT) is a promising treatment option aimed at improving the management of localised prostate cancer. This masterclass will…
PCaVision is live on INVESDOR
Our crowd-investment page is now live to scale PCaVision across European urology clinics! You can invest now, starting from €363…
PCaVision is joining EMUC25 !
Also this year, PCaVision is attending the European Multidisciplinary Congress on Urological Cancers. Are you attending? Be sure to attend…
Join Us at Focal+ 2025 in Maryland!
We are pleased to announce that PCaVision will be attending Focal+ 2025! This premier event provides a fantastic opportunity to…
Angiogenesis Analytics to Attend BAUS Section of Oncology 2025 Annual Meeting
Also this year, Angiogenesis Analytics will be participating in the BAUS Section of Oncology Annual Meeting. This annual event brings…
A new publication on multiparametric ultrasound (mpUS) and PCaVision is now available!
A recent study highlights the effectiveness of 3D multiparametric ultrasound (mpUS) and PCaVision in accurately diagnosing prostate cancer. Therefore, a…
Exciting News: Protocol Paper Released for Our Ongoing Clinical Trial!
We are thrilled to announce the release of our protocol paper detailing our ongoing clinical trial focused on prostate cancer…